Comparative Pharmacology
Head-to-head clinical analysis: PHOSLYRA versus RENVELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLYRA versus RENVELA.
PHOSLYRA vs RENVELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Renvela (sevelamer carbonate) is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, inhibiting phosphate absorption and reducing serum phosphate levels. It also binds bile acids, leading to decreased LDL cholesterol.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
Adults: 800 mg orally three times daily with meals; titrate based on serum phosphorus levels up to 2400 mg per meal (7200 mg/day maximum).
None Documented
None Documented
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Not applicable as sevelamer is not absorbed. No systemic half-life; local gastrointestinal transit time is approximately 3-4 hours.
Renal 100% as unchanged drug, no biliary or fecal elimination.
Sevelamer carbonate is not absorbed systemically; excretion is entirely fecal as the parent compound. Less than 0.01% is absorbed and excreted renally.
Category C
Category C
Phosphate Binder
Phosphate Binder